Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,428 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Product Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat

NCT02935894
View directory record Official record
Conditions
Stability & Variability of Lipid-derived Molecules in Sweat
Interventions
Ibuprofen, Physiological induction of sweating, Pilocarpine
Drug · Other
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
20 Years to 40 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 21, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

A Extension Study of Udenafil in Adolescents

NCT03013751
View directory record Official record
Conditions
Functional Single Ventricle Heart Disease
Interventions
Udenafil
Drug
Lead sponsor
Mezzion Pharma Co. Ltd
Industry
Eligibility
12 Years to 18 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 21, 2026, 4:56 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Treating PCOS With Semaglutide vs Active Lifestyle Intervention

NCT03919929
View directory record Official record
Conditions
PCOS, Adolescent Obesity, NAFLD
Interventions
Semaglutide 3mg and 7mg [Rybelsus], Weight loss diet
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 21, 2026, 4:56 AM EDT
Terminated Not applicable Interventional

The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens

NCT02998502
View directory record Official record
Conditions
Anxiety, Panic Disorder
Interventions
Freespira Breathing System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
9 Years to 17 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 21, 2026, 4:56 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms

NCT00002357
View directory record Official record
Conditions
HIV Infections
Interventions
HBY 097, Zidovudine
Drug
Lead sponsor
Hoechst Marion Roussel
Industry
Eligibility
13 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 4:56 AM EDT
Terminated Phase 1 Interventional

A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors

NCT05387265
View directory record Official record
Conditions
Solid Tumors
Interventions
CX-904
Drug
Lead sponsor
CytomX Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Denver, Colorado • Nashville, Tennessee • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 21, 2026, 4:56 AM EDT
Not listed Phase 1 Interventional

Ketamine for Major Depressive Disorder

NCT03721900
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SHX-001 Active low dose, Placebo, SHX-001 Active High dose
Drug
Lead sponsor
Shenox Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Gaithersburg, Maryland • Boston, Massachusetts • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 21, 2026, 4:56 AM EDT
Not listed Not applicable Interventional

Zypan Functional Dyspepsia

NCT06320379
View directory record Official record
Conditions
Dyspepsia
Interventions
Zypan, Placebo Comparator
Dietary Supplement
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 21, 2026, 4:56 AM EDT
Completed Phase 2 Interventional Results available

To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants

NCT04914377
View directory record Official record
Conditions
Covid19
Interventions
TQ Formula/Tab
Drug
Lead sponsor
Novatek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
San Diego, California • Hialeah, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 21, 2026, 4:56 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy

NCT01986777
View directory record Official record
Conditions
Cognitive Impairments, RRSO
Interventions
lisdexamfetamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 60 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 21, 2026, 4:56 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas

NCT00995007
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
Interventions
ZD6474 (Vandetanib), Carboplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 21, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, COBI, ATV, DRV, NRTI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 21, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

NCT03959241
View directory record Official record
Conditions
Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
Interventions
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, Cyclophosphamide
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 21, 2026, 4:56 AM EDT
Terminated Phase 1 Interventional

Vaccine Therapy in Treating Patients With Kidney Cancer

NCT00014131
View directory record Official record
Conditions
Kidney Cancer
Interventions
Biological/Vaccine: therapeutic autologous dendritic cells.
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
16 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 21, 2026, 4:56 AM EDT
Not listed Phase 3 Interventional

Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

NCT00005002
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, HIV-1 Immunogen, Nelfinavir mesylate
Drug · Biological
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 4:56 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

What is the Role of Type III/IV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise?

NCT07452094
View directory record Official record
Conditions
Placebo - Control, Experimental
Interventions
EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Drug
Lead sponsor
Northern Arizona University
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Flagstaff, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 21, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate

NCT03659929
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Amphetamine Sulfate, Placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
31
States / cities
Encino, California • Garden Grove, California • Newport Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 21, 2026, 4:56 AM EDT
Terminated Phase 2 Interventional Results available

Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis

NCT00670202
View directory record Official record
Conditions
Carotid Stenosis
Interventions
Fasudil Hydrochloride, Placebo Oral Tablet
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 21, 2026, 4:56 AM EDT
Terminated Phase 3 Interventional Results available

Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)

NCT02932475
View directory record Official record
Conditions
Diabetes, Pregnancy
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Jackson, Mississippi + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 21, 2026, 4:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Supporting Tailored And Responsive PrEP in Rural North Carolina

NCT05984030
View directory record Official record
Conditions
HIV Pre-Exposure Prophylaxis
Interventions
PrEP Navigation Services, Telehealth PrEP Services Referral, HealthMpowerment Digital Health Intervention - Enhanced, HealthMpowerment Digital Health Intervention - Basic
Other · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 39 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 21, 2026, 4:56 AM EDT
Completed Phase 1 Interventional

Oral AMXT 1501 Dicaprate in Combination With DFMO

NCT03536728
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
Interventions
AMXT1501, DFMO
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Austin, Texas • Houston, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 21, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

NCT02873936
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, csDMARDs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
55
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 21, 2026, 4:56 AM EDT
Completed Not applicable Interventional Results available

A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation

NCT00408200
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
propafenone; flecainide; sotalol; dofetilide, Radiofrequency catheter ablation
Drug · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 21, 2026, 4:56 AM EDT
Terminated Phase 2 Interventional Results available

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

NCT00572156
View directory record Official record
Conditions
Insulin-like Growth Factor-1 Deficiency
Interventions
NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
Drug
Lead sponsor
Ipsen
Industry
Eligibility
5 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 21, 2026, 4:56 AM EDT